Position Papers
-
Global Call to Action for Thalassaemia
This important document, prepared by TIF in close collaboration with the Government of Cyprus, serves as a comprehensive and evidence-based guide to strengthening national responses…
Read More » -
Position Paper: The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)
This Position Paper discusses the significant barriers that affect patient access to Advanced Therapy Medicinal Products (ATMPs) and calls for policymakers, healthcare professionals, and society at large to acknowledge and…
Read More » -
Position Paper: Strengthening the Resilience of EU Health Systems
This Position Paper discusses the increasing vulnerability of national health systems to new and emerging public health challenges, with a particular focus on the growing prevalence of thalassaemia and its…
Read More » -
Social Health Protection for People with Thalassaemia│TIF’s Disability Risk Assessment Chart
In an effort to safeguard the social health protection of people with thalassaemia and other haemoglobin disorders, TIF has taken the initiative to create a “Disability Risk Assessment Chart”, encompassing…
Read More » -
Position Statement: EU Regulation for Blood, Tissues and Cells
The Thalassaemia International Federation (TIF) welcomes the European Commission’s proposal on the new EU Regulation for Blood, Tissues and Cells as a highly significant policy step towards improving the protection…
Read More » -
Position Statement: Demanding Access to Existing and Upcoming Gene Therapies for Beta Thalassaemia
The Thalassaemia International Federation (TIF) is expressing its grave disappointment over the recent announcement of Bluebird Bio, concerning the “wind-down” of its operations in Europe and the exclusive disposal of…
Read More » -
Position Statement: Addressing Blood Supply Issues Linked to COVID-19 Vaccination Deferral Times
In this Position Statement, TIF wishes to address and clarify to the extent possible basic questions that oftentimes concern blood donors with regard to Covid-19 vaccination and blood donation.
Read More » -
Position Statement: Accessibility of Gene Therapy for Thalassaemia
Gene therapy has been a long-awaited scientific development for thalassaemia patients and has given hope, optimism, and opened new horizons. It is imperative for ground-breaking scientific advances and innovative therapies…
Read More » -
EU Policy Recommendations for Thalassaemia and Sickle Cell Disease
This document has been drafted in the context of the activities of the TIF multiannual programme (2018-2021), “Thalassaemia In Action” (THALIA). Its aim is to provide an overview of the…
Read More » -
Position Statement: COVID-19 Vaccines & Haemoglobin Disorders
In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, TIF herein presents the Federation’s…
Read More »